Why I’d sell this FTSE 250 flop and buy AstraZeneca plc instead

G A Chester sees a much stronger investment case for AstraZeneca plc (LON:AZN) than this FTSE 250 (INDEXFTSE:MCX) stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I named outsourcer Mitie (LSE: MTO) as ‘The one FTSE 250 stock I’d sell ASAP’ back in May. I showed, among other things, how the company’s accrued income (income booked in the accounts but not yet received) had been rising dramatically over the years, well ahead of its peers and in a sector not renowned for conservative revenue recognition.

Its longstanding chief executive and finance director had both departed and I expected major kitchen-sinking from the new chief executive in the form of impairments, a suspension of the dividend and a discounted fundraising at some point to shore up the balance sheet. In short, a pretty grim outlook for the company whose shares were then trading at 221p.

Up and down

To my consternation, the shares began to soar. Full-year results in June saw the dividend suspended but impairments were far less than I was anticipating and net debt had fallen to £147m from £178m. The shares reached a high of almost 300p in the wake of the results. So much for my ‘sell’ rating at 221p!

However, while short-term traders may have profited, the shares soon began to fall back and after the company released its half-year results earlier this week, they’re down to 206p, as I’m writing. Net debt was back up, to £173m, and there’s also £60m debt due to be repaid in December. Nevertheless, the board declared a small interim dividend (gross cost £0.5m).

I continue to think we’ll see further impairments in due course, including to goodwill, of which there’s £274m on the balance sheet, compared with net assets of less than £100m. Goodwill of £107m was written down to zero for its disposed-of healthcare business and there’s been a £15m writedown on its held-for-sale property management arm. But no writedowns for continuing operations.

I also still feel a dilutive fundraising is likely at some point. If so, 12-month forward earnings-per-share (EPS) forecasts would have to be lowered, making a nonsense of a current price-to-earnings (P/E) ratio of 11. Personally, I continue to rate the stock a ‘sell’, although investors should also consider the bull case.

Turning point

In contrast, I’m convinced FTSE 100 pharma giant AstraZeneca (LSE: AZN) has a terrific outlook and I rate the stock — trading at under 5,000p, as I’m writing — a ‘buy’. This despite EPS having fallen a cumulative 40% since 2011 and a further 20% drop forecast by City analysts this year.

The company is weathering a period of patent expiries and generic competition but the fall in EPS is forecast to bottom out in 2018. The business has been restructured and reinvigorated and my confidence in the medium-to-long-term outlook for earnings growth is bolstered by Q3 results from the company earlier this month.

Of particular note, management advised that the impact from patent expiries is receding. Meanwhile, new drugs are coming through fast. There were seven regulatory approvals during the period and other positive developments in the late-stage pipeline. Further significant news flow is expected during 2018.

A P/E of 18 may not sound cheap but this will drop rapidly if, as I anticipate, the company meets forecasts of accelerating EPS growth of 15% in 2019 and 20% in 2020. With the board having also maintained the dividend through the doldrums, giving a nice running yield of 4.2% at current exchange rates, the shares look very buyable to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

14.5bn reasons why I think the Legal & General share price is at least 11% undervalued

According to our writer, the Legal & General share price doesn’t appear to reflect the underlying profitability of the business. 

Read more »

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »